| 3 | Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia显示文摘Correction to:Signal Transduction and Targeted Therapy(2022)7:1–13,http://gffzzd3cc09b8251d45dfsop66ckkvp5wp6b5f.ffgz.tsg.suse.edu.cn/10.1038/s41392-021-00870-3 In the original version of this article,given name of 4th author Yannan Jia was incorrectly published as Yanan Jia.The original article has been corrected.Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,which permits use,sharing,adaptation,distribution and reproduction in any medium or format,as long as you give appropriate credit to the original author(s)and the source. | Qi Zhang Bridget Riley-Gillis Lina Han Yannan Jia Alessia Lodi Haijiao Zhang Saravanan Ganesan Rongqing Pan Sergej N.Konoplev Shannon R.Sweeney Jeremy A.Ryan Yulia Jitkova Kenneth Dunner Jr Shaun E.Grosskurth Priyanka Vijay Sujana Ghosh Charles Lu Wencai Ma Stephen Kurtz Vivian R.Ruvolo Helen Ma Connie C.Weng Cassandra L.Ramage Natalia Baran Ce Shi Tianyu Cai Richard Eric Davis Venkata L.Battula Yingchang Mi Jing Wang Courtney D.DiNardo Michael Andreeff Jeffery W.Tyner Aaron Schimmer Anthony Letai Rose Ann Padua Carlos E.Bueso-Ramos Stefano Tiziani Joel Leverson Relja Popovic Marina Konopleva | 2022 | Signal Transduction and Targeted Therapy2022，7，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员